Management of Diabetes Mellitus with Drug Doses

Type 2 Diabetes – Initial Therapy

Start metformin 500 mg once or twice daily with meals at diagnosis, titrate by 500 mg weekly to 2000 mg daily (1000 mg twice daily), and continue indefinitely unless contraindicated. 1, 2

Metformin reduces all-cause mortality by approximately 36% and cardiovascular mortality by 39% compared with conventional therapy, making it mandatory first-line therapy. 1
The maximum effective dose is 2000 mg daily; doses above this provide minimal additional benefit and increase gastrointestinal intolerance. 1, 2
Extended-release formulations (taken once daily) provide comparable efficacy with fewer gastrointestinal side effects. 3

Renal Function Dosing for Metformin

eGFR (mL/min/1.73 m²)	Metformin Dosing
≥ 60	Full dose up to 2000 mg daily
45–59	Reduce to 50% (≈1000 mg daily)
30–44	Limit to 1000 mg daily; provide sick-day guidance
< 30	Discontinue due to lactic acidosis risk

1, 2, 3, 4

Monitor vitamin B12 annually in patients on long-term metformin, especially those with anemia or peripheral neuropathy. 1, 2, 3

Type 2 Diabetes – Second-Line Therapy (After 3 Months)

If HbA1c remains > 7–8% after 3 months of metformin plus lifestyle modifications, add either an SGLT-2 inhibitor or a GLP-1 receptor agonist immediately—do not delay beyond 3 months. 1, 2

Choose SGLT-2 Inhibitor When:

Heart failure (especially reduced ejection fraction) is present—SGLT-2 inhibitors reduce heart-failure hospitalizations more than any other glucose-lowering drug. 1, 3
Chronic kidney disease (eGFR 30–90 mL/min/1.73 m² or albumin-to-creatinine ratio > 200 mg/g) is present—they slow CKD progression by 24–39%. 1, 3
Cardiovascular mortality reduction is the priority—empagliflozin reduces cardiovascular death by 38%. 1, 3

SGLT-2 Inhibitor Dosing

Agent	Starting Dose	Maximum Dose	Renal Threshold
Empagliflozin	10 mg once daily	25 mg daily	eGFR ≥ 20 mL/min/1.73 m²
Dapagliflozin	5 mg once daily	10 mg daily	eGFR ≥ 25 mL/min/1.73 m²
Canagliflozin	100 mg once daily	300 mg daily (if eGFR ≥ 60)	eGFR ≥ 30 mL/min/1.73 m²

1, 2, 3

SGLT-2 inhibitors retain cardiovascular and renal benefits even when eGFR falls below the initiation threshold; continue therapy until dialysis or transplantation. 3

Choose GLP-1 Receptor Agonist When:

Stroke risk is elevated—GLP-1 agonists specifically reduce stroke incidence. 1, 2
Substantial weight loss (> 10% body weight) is a therapeutic goal—they achieve 2–5 kg weight loss (semaglutide up to 10 kg). 1, 2
All-cause mortality reduction is the priority—liraglutide reduces cardiovascular death by 22%. 1, 3

GLP-1 Receptor Agonist Dosing

Agent	Starting Dose	Titration Schedule	Maximum Dose
Semaglutide (SC)	0.25 mg weekly × 4 weeks	→ 0.5 mg weekly × 4 weeks	1.0–2.4 mg weekly
Semaglutide (oral)	3 mg daily × 30 days	→ 7 mg daily × 30 days	14 mg daily
Liraglutide	0.6 mg daily × 1 week	→ 1.2 mg daily	1.8–3.0 mg daily
Dulaglutide	0.75 mg weekly	→ 1.5 mg weekly	4.5 mg weekly

1, 2

GLP-1 receptor agonists provide an additional 0.6–0.8% HbA1c reduction (semaglutide up to 1.5%) with minimal hypoglycemia risk when not combined with sulfonylureas or insulin. 1, 2, 3
No renal dose adjustment is required for semaglutide, liraglutide, or dulaglutide. 1

Type 2 Diabetes – High-Risk Patients (CVD, HF, or CKD)

In patients with established cardiovascular disease, heart failure, or chronic kidney disease, start metformin PLUS an SGLT-2 inhibitor or GLP-1 receptor agonist at diagnosis, regardless of baseline HbA1c—do not wait for metformin "failure." 1, 2, 3

Delaying organ-protective agents in high-risk patients increases morbidity and mortality. 1, 3
Both agents should be initiated early because most patients rapidly progress to needing combination therapy. 1

Type 2 Diabetes – Severe Hyperglycemia (HbA1c ≥ 10% or Glucose ≥ 300 mg/dL)

Start metformin 500 mg twice daily PLUS basal insulin 10 units at bedtime (or 0.1–0.2 U/kg) immediately—do not attempt oral monotherapy. 1, 2

Basal Insulin Initiation and Titration

Begin with 10 units once daily at bedtime or 0.1–0.2 U/kg body weight (use higher end for HbA1c ≥ 10%). 1, 2
Titrate by 2–4 units every 3 days until fasting glucose is 80–130 mg/dL without hypoglycemia. 1, 2
If hypoglycemia occurs, reduce insulin dose by 10–20%. 2
Never discontinue metformin when adding insulin—it reduces insulin requirements by 20–30%, prevents weight gain, and provides cardiovascular mortality benefit. 1, 2

If HbA1c Remains > 7% After 3 Months

Add a GLP-1 receptor agonist (not more insulin) to the metformin + basal insulin regimen. 1, 2

GLP-1 agonists provide an additional 0.6–0.8% HbA1c reduction, promote 2–5 kg weight loss, and reduce major adverse cardiovascular events by 22–26%. 1, 2
They carry minimal hypoglycemia risk when not combined with sulfonylureas. 1, 2

Type 2 Diabetes – Glycemic Targets

Target HbA1c 7–8% for most adults to balance microvascular protection against hypoglycemia risk. 1, 2, 3

De-intensify therapy when HbA1c falls below 6.5% to avoid hypoglycemia and overtreatment. 1, 2
Consider HbA1c < 6.5% only for younger patients with short disease duration, long life expectancy, and no hypoglycemia risk. 2
Adopt HbA1c 7.5–8.5% for older adults (≥ 65 years), those with limited life expectancy (< 10 years), advanced complications, extensive comorbidities, or prior severe hypoglycemia. 2

Type 2 Diabetes – Monitoring and Follow-Up

Reassess HbA1c at 3 months after any therapy change—this is the longest acceptable interval before intensification. 1, 2
Once HbA1c is at target, continue quarterly monitoring. 2, 3
Check eGFR at baseline and annually (every 3–6 months if eGFR 30–59 mL/min/1.73 m²). 1, 3
Self-monitoring of blood glucose is unnecessary when metformin is combined with an SGLT-2 inhibitor or GLP-1 agonist, as these regimens carry minimal hypoglycemia risk. 1

Type 2 Diabetes – Critical Safety Measures

When SGLT-2 inhibitors or GLP-1 agonists achieve adequate glycemic control, immediately reduce or discontinue sulfonylureas or long-acting insulins due to severe hypoglycemia risk. 1, 2

Sulfonylureas increase hypoglycemia risk 7-fold and are associated with 2-fold higher all-cause mortality compared with metformin. 2
Never add DPP-4 inhibitors to metformin—they do not reduce morbidity or all-cause mortality despite lowering HbA1c. 1
Never combine GLP-1 agonists with DPP-4 inhibitors—no additional benefit has been demonstrated. 1, 2

Type 1 Diabetes – Basal-Bolus Insulin Therapy

Initiate total daily insulin dose of 0.3–0.5 U/kg/day, divided 50% as basal insulin (once daily) and 50% as prandial insulin (spread over three meals). 2

Basal Insulin Component

Use long-acting analogs (glargine, degludec, or detemir) once daily at bedtime for lower hypoglycemia risk. 2, 3
Titrate by 2–4 units every 3 days until fasting glucose is 80–130 mg/dL. 2

Prandial Insulin Component

Start with 4 units of rapid-acting insulin before the largest meal or 10% of basal dose. 2
Titrate by 1–2 units every 3 days based on 2-hour post-prandial glucose readings. 2
Target post-prandial glucose < 180 mg/dL. 5

Monitoring in Type 1 Diabetes

Daily fasting and pre-meal glucose checks are mandatory during insulin titration. 2
HbA1c target is < 7% for most adults without complications. 2, 3
If hypoglycemia occurs, identify the cause and reduce the corresponding insulin dose by 10–20%. 2

Common Pitfalls to Avoid

Never delay insulin initiation when HbA1c ≥ 10% or glucose ≥ 300 mg/dL—oral agents alone cannot achieve control. 1, 2
Never discontinue metformin when adding insulin or other agents unless eGFR < 30 mL/min/1.73 m². 1, 2, 3
Never postpone intensification beyond 3 months when HbA1c remains above target—therapeutic inertia increases complication risk. 1, 2, 3
Never continue sulfonylureas when adding insulin or GLP-1 agonists—they markedly increase hypoglycemia risk without cardiovascular benefit. 1, 2
Never use metformin when eGFR < 30 mL/min/1.73 m² due to lactic acidosis risk. 1, 3, 4, 6

Help us tailor your experience